Clinical Trial Update: Open-Label Natalizumab Safety Extension Study [Phase 3]

View source ↗

Summary

Open-label safety extension study of natalizumab in multiple sclerosis, a Phase 3 trial sponsored by Biogen; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED